Adaptimmune Therapeutics plc
ADAPNASDAQHealthcare
$0.05
$-0.00(-3.00%)
Market Cap$75157679
P/E Ratio—
52W High$0.86
52W Low$0.0202
Adaptimmune Therapeutics plc（ADAP）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ADAP · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.07B) | ($0.11B) | ($0.17B) | ($0.16B) | ($0.13B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.02B | $0.02B | $0.01B |
| Change in Working Capital | ($0.04B) | ($0.02B) | ($0.00B) | $0.13B | $0.06B |
| Net Cash from Operations | ($0.07B) | ($0.14B) | ($0.14B) | $0.01B | ($0.05B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.03B) | ($0.01B) | ($0.00B) |
| Purchases of Investments | ($0.10B) | ($0.08B) | ($0.05B) | ($0.14B) | ($0.38B) |
| Sales of Investments | $0.04B | $0.21B | $0.17B | $0.22B | $0.11B |
| Net Cash from Investing | ($0.06B) | $0.18B | $0.09B | $0.08B | ($0.28B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.05B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.08B | $0.00B | $0.01B | $0.00B | $0.34B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.08B) | ($0.15B) | ($0.17B) | $0.00B | ($0.06B) |
| FCF Margin %(computed) | -42.65% | -241.80% | -631.76% | 31.68% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Adaptimmune Therapeutics plc
关于Adaptimmune Therapeutics plc（ADAP）现金流量表
Adaptimmune Therapeutics plc 2024财年经营活动现金流($0.07B)，自由现金流($0.08B)（FCF利润率-42.65%），资本支出($0.00B)。
常见问题
ADAP · 4 问Adaptimmune Therapeutics plc 2024财年自由现金流($0.08B)，同比up47.9%。
ADAP free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10